line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,JBCHEPHARM.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.256719,JBCHEPHARM.NS
Normalized EBITDA,2025-03-31 00:00:00,10701600000.0,JBCHEPHARM.NS
Total Unusual Items,2025-03-31 00:00:00,,JBCHEPHARM.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,,JBCHEPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,6595800000.0,JBCHEPHARM.NS
Reconciled Depreciation,2025-03-31 00:00:00,1710400000.0,JBCHEPHARM.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,13165500000.0,JBCHEPHARM.NS
EBITDA,2025-03-31 00:00:00,10701600000.0,JBCHEPHARM.NS
EBIT,2025-03-31 00:00:00,8991200000.0,JBCHEPHARM.NS
Net Interest Income,2025-03-31 00:00:00,-117300000.0,JBCHEPHARM.NS
Interest Expense,2025-03-31 00:00:00,117300000.0,JBCHEPHARM.NS
Interest Income,2025-03-31 00:00:00,,JBCHEPHARM.NS
Normalized Income,2025-03-31 00:00:00,6595800000.0,JBCHEPHARM.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,6595800000.0,JBCHEPHARM.NS
Total Expenses,2025-03-31 00:00:00,30571900000.0,JBCHEPHARM.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,JBCHEPHARM.NS
Diluted Average Shares,2025-03-31 00:00:00,,JBCHEPHARM.NS
Basic Average Shares,2025-03-31 00:00:00,,JBCHEPHARM.NS
Diluted EPS,2025-03-31 00:00:00,,JBCHEPHARM.NS
Basic EPS,2025-03-31 00:00:00,,JBCHEPHARM.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,6595800000.0,JBCHEPHARM.NS
Net Income Common Stockholders,2025-03-31 00:00:00,6595800000.0,JBCHEPHARM.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,JBCHEPHARM.NS
Net Income,2025-03-31 00:00:00,6595800000.0,JBCHEPHARM.NS
Minority Interests,2025-03-31 00:00:00,0.0,JBCHEPHARM.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,6595800000.0,JBCHEPHARM.NS
Net Income Continuous Operations,2025-03-31 00:00:00,6595800000.0,JBCHEPHARM.NS
Tax Provision,2025-03-31 00:00:00,2278100000.0,JBCHEPHARM.NS
Pretax Income,2025-03-31 00:00:00,8873900000.0,JBCHEPHARM.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,383200000.0,JBCHEPHARM.NS
Special Income Charges,2025-03-31 00:00:00,,JBCHEPHARM.NS
Other Special Charges,2025-03-31 00:00:00,,JBCHEPHARM.NS
Write Off,2025-03-31 00:00:00,,JBCHEPHARM.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-117300000.0,JBCHEPHARM.NS
Total Other Finance Cost,2025-03-31 00:00:00,,JBCHEPHARM.NS
Interest Expense Non Operating,2025-03-31 00:00:00,117300000.0,JBCHEPHARM.NS
Interest Income Non Operating,2025-03-31 00:00:00,,JBCHEPHARM.NS
Operating Income,2025-03-31 00:00:00,8608000000.0,JBCHEPHARM.NS
Operating Expense,2025-03-31 00:00:00,17406400000.0,JBCHEPHARM.NS
Other Operating Expenses,2025-03-31 00:00:00,8819900000.0,JBCHEPHARM.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,1710400000.0,JBCHEPHARM.NS
Depreciation Income Statement,2025-03-31 00:00:00,1710400000.0,JBCHEPHARM.NS
Selling General And Administration,2025-03-31 00:00:00,,JBCHEPHARM.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,JBCHEPHARM.NS
General And Administrative Expense,2025-03-31 00:00:00,,JBCHEPHARM.NS
Rent And Landing Fees,2025-03-31 00:00:00,,JBCHEPHARM.NS
Gross Profit,2025-03-31 00:00:00,26014400000.0,JBCHEPHARM.NS
Cost Of Revenue,2025-03-31 00:00:00,13165500000.0,JBCHEPHARM.NS
Total Revenue,2025-03-31 00:00:00,39179900000.0,JBCHEPHARM.NS
Operating Revenue,2025-03-31 00:00:00,39179900000.0,JBCHEPHARM.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,JBCHEPHARM.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.264641,JBCHEPHARM.NS
Normalized EBITDA,2024-03-31 00:00:00,9341600000.0,JBCHEPHARM.NS
Total Unusual Items,2024-03-31 00:00:00,328652000.0,JBCHEPHARM.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,328652000.0,JBCHEPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,5526300000.0,JBCHEPHARM.NS
Reconciled Depreciation,2024-03-31 00:00:00,1383200000.0,JBCHEPHARM.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,11820500000.0,JBCHEPHARM.NS
EBITDA,2024-03-31 00:00:00,9341600000.0,JBCHEPHARM.NS
EBIT,2024-03-31 00:00:00,7958400000.0,JBCHEPHARM.NS
Net Interest Income,2024-03-31 00:00:00,-443300000.0,JBCHEPHARM.NS
Interest Expense,2024-03-31 00:00:00,443300000.0,JBCHEPHARM.NS
Interest Income,2024-03-31 00:00:00,44277000.0,JBCHEPHARM.NS
Normalized Income,2024-03-31 00:00:00,5526300000.0,JBCHEPHARM.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,5526300000.0,JBCHEPHARM.NS
Total Expenses,2024-03-31 00:00:00,27256100000.0,JBCHEPHARM.NS
Rent Expense Supplemental,2024-03-31 00:00:00,20169000.0,JBCHEPHARM.NS
Diluted Average Shares,2024-03-31 00:00:00,158573888.0,JBCHEPHARM.NS
Basic Average Shares,2024-03-31 00:00:00,154971957.0,JBCHEPHARM.NS
Diluted EPS,2024-03-31 00:00:00,34.85,JBCHEPHARM.NS
Basic EPS,2024-03-31 00:00:00,35.66,JBCHEPHARM.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,5526300000.0,JBCHEPHARM.NS
Net Income Common Stockholders,2024-03-31 00:00:00,5526300000.0,JBCHEPHARM.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,JBCHEPHARM.NS
Net Income,2024-03-31 00:00:00,5526300000.0,JBCHEPHARM.NS
Minority Interests,2024-03-31 00:00:00,0.0,JBCHEPHARM.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,5526300000.0,JBCHEPHARM.NS
Net Income Continuous Operations,2024-03-31 00:00:00,5526300000.0,JBCHEPHARM.NS
Tax Provision,2024-03-31 00:00:00,1988800000.0,JBCHEPHARM.NS
Pretax Income,2024-03-31 00:00:00,7515100000.0,JBCHEPHARM.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,372700000.0,JBCHEPHARM.NS
Special Income Charges,2024-03-31 00:00:00,1225000.0,JBCHEPHARM.NS
Other Special Charges,2024-03-31 00:00:00,-1225000.0,JBCHEPHARM.NS
Write Off,2024-03-31 00:00:00,,JBCHEPHARM.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-443300000.0,JBCHEPHARM.NS
Total Other Finance Cost,2024-03-31 00:00:00,6762000.0,JBCHEPHARM.NS
Interest Expense Non Operating,2024-03-31 00:00:00,443300000.0,JBCHEPHARM.NS
Interest Income Non Operating,2024-03-31 00:00:00,44277000.0,JBCHEPHARM.NS
Operating Income,2024-03-31 00:00:00,7585700000.0,JBCHEPHARM.NS
Operating Expense,2024-03-31 00:00:00,15435600000.0,JBCHEPHARM.NS
Other Operating Expenses,2024-03-31 00:00:00,8038300000.0,JBCHEPHARM.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,1383200000.0,JBCHEPHARM.NS
Depreciation Income Statement,2024-03-31 00:00:00,1383200000.0,JBCHEPHARM.NS
Selling General And Administration,2024-03-31 00:00:00,4155098000.0,JBCHEPHARM.NS
Selling And Marketing Expense,2024-03-31 00:00:00,3818072000.0,JBCHEPHARM.NS
General And Administrative Expense,2024-03-31 00:00:00,337026000.0,JBCHEPHARM.NS
Rent And Landing Fees,2024-03-31 00:00:00,20169000.0,JBCHEPHARM.NS
Gross Profit,2024-03-31 00:00:00,23021300000.0,JBCHEPHARM.NS
Cost Of Revenue,2024-03-31 00:00:00,11820500000.0,JBCHEPHARM.NS
Total Revenue,2024-03-31 00:00:00,34841800000.0,JBCHEPHARM.NS
Operating Revenue,2024-03-31 00:00:00,34841800000.0,JBCHEPHARM.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,19810906.148702,JBCHEPHARM.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.261561,JBCHEPHARM.NS
Normalized EBITDA,2023-03-31 00:00:00,6974738000.0,JBCHEPHARM.NS
Total Unusual Items,2023-03-31 00:00:00,75741000.0,JBCHEPHARM.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,75741000.0,JBCHEPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,4098355000.0,JBCHEPHARM.NS
Reconciled Depreciation,2023-03-31 00:00:00,1144069000.0,JBCHEPHARM.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,11847974000.0,JBCHEPHARM.NS
EBITDA,2023-03-31 00:00:00,7050479000.0,JBCHEPHARM.NS
EBIT,2023-03-31 00:00:00,5906410000.0,JBCHEPHARM.NS
Net Interest Income,2023-03-31 00:00:00,-335169000.0,JBCHEPHARM.NS
Interest Expense,2023-03-31 00:00:00,354084000.0,JBCHEPHARM.NS
Interest Income,2023-03-31 00:00:00,25362000.0,JBCHEPHARM.NS
Normalized Income,2023-03-31 00:00:00,4042424906.148702,JBCHEPHARM.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,4098355000.0,JBCHEPHARM.NS
Total Expenses,2023-03-31 00:00:00,25290168000.0,JBCHEPHARM.NS
Rent Expense Supplemental,2023-03-31 00:00:00,29508000.0,JBCHEPHARM.NS
Diluted Average Shares,2023-03-31 00:00:00,78308798.0,JBCHEPHARM.NS
Basic Average Shares,2023-03-31 00:00:00,77324995.0,JBCHEPHARM.NS
Diluted EPS,2023-03-31 00:00:00,26.17,JBCHEPHARM.NS
Basic EPS,2023-03-31 00:00:00,26.5,JBCHEPHARM.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,4098355000.0,JBCHEPHARM.NS
Net Income Common Stockholders,2023-03-31 00:00:00,4098355000.0,JBCHEPHARM.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,JBCHEPHARM.NS
Net Income,2023-03-31 00:00:00,4098355000.0,JBCHEPHARM.NS
Minority Interests,2023-03-31 00:00:00,-1698000.0,JBCHEPHARM.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,4100053000.0,JBCHEPHARM.NS
Net Income Continuous Operations,2023-03-31 00:00:00,4100053000.0,JBCHEPHARM.NS
Tax Provision,2023-03-31 00:00:00,1452273000.0,JBCHEPHARM.NS
Pretax Income,2023-03-31 00:00:00,5552326000.0,JBCHEPHARM.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,3658000.0,JBCHEPHARM.NS
Special Income Charges,2023-03-31 00:00:00,6743000.0,JBCHEPHARM.NS
Other Special Charges,2023-03-31 00:00:00,-6743000.0,JBCHEPHARM.NS
Write Off,2023-03-31 00:00:00,,JBCHEPHARM.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,-335169000.0,JBCHEPHARM.NS
Total Other Finance Cost,2023-03-31 00:00:00,6447000.0,JBCHEPHARM.NS
Interest Expense Non Operating,2023-03-31 00:00:00,354084000.0,JBCHEPHARM.NS
Interest Income Non Operating,2023-03-31 00:00:00,25362000.0,JBCHEPHARM.NS
Operating Income,2023-03-31 00:00:00,5874888000.0,JBCHEPHARM.NS
Operating Expense,2023-03-31 00:00:00,13442194000.0,JBCHEPHARM.NS
Other Operating Expenses,2023-03-31 00:00:00,3038827000.0,JBCHEPHARM.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,1144069000.0,JBCHEPHARM.NS
Depreciation Income Statement,2023-03-31 00:00:00,1144069000.0,JBCHEPHARM.NS
Selling General And Administration,2023-03-31 00:00:00,3752897000.0,JBCHEPHARM.NS
Selling And Marketing Expense,2023-03-31 00:00:00,3384979000.0,JBCHEPHARM.NS
General And Administrative Expense,2023-03-31 00:00:00,367918000.0,JBCHEPHARM.NS
Rent And Landing Fees,2023-03-31 00:00:00,29508000.0,JBCHEPHARM.NS
Gross Profit,2023-03-31 00:00:00,19317082000.0,JBCHEPHARM.NS
Cost Of Revenue,2023-03-31 00:00:00,11847974000.0,JBCHEPHARM.NS
Total Revenue,2023-03-31 00:00:00,31165056000.0,JBCHEPHARM.NS
Operating Revenue,2023-03-31 00:00:00,31165056000.0,JBCHEPHARM.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,0.0,JBCHEPHARM.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.235413,JBCHEPHARM.NS
Normalized EBITDA,2022-03-31 00:00:00,5826800000.0,JBCHEPHARM.NS
Total Unusual Items,2022-03-31 00:00:00,374479000.0,JBCHEPHARM.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,374479000.0,JBCHEPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,3853600000.0,JBCHEPHARM.NS
Reconciled Depreciation,2022-03-31 00:00:00,726600000.0,JBCHEPHARM.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,8429400000.0,JBCHEPHARM.NS
EBITDA,2022-03-31 00:00:00,5826800000.0,JBCHEPHARM.NS
EBIT,2022-03-31 00:00:00,5100200000.0,JBCHEPHARM.NS
Net Interest Income,2022-03-31 00:00:00,-51200000.0,JBCHEPHARM.NS
Interest Expense,2022-03-31 00:00:00,51200000.0,JBCHEPHARM.NS
Interest Income,2022-03-31 00:00:00,9343000.0,JBCHEPHARM.NS
Normalized Income,2022-03-31 00:00:00,3853600000.0,JBCHEPHARM.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,3853600000.0,JBCHEPHARM.NS
Total Expenses,2022-03-31 00:00:00,19534500000.0,JBCHEPHARM.NS
Rent Expense Supplemental,2022-03-31 00:00:00,13403000.0,JBCHEPHARM.NS
Diluted Average Shares,2022-03-31 00:00:00,154700923.0,JBCHEPHARM.NS
Basic Average Shares,2022-03-31 00:00:00,154576815.0,JBCHEPHARM.NS
Diluted EPS,2022-03-31 00:00:00,24.91,JBCHEPHARM.NS
Basic EPS,2022-03-31 00:00:00,24.93,JBCHEPHARM.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,3853600000.0,JBCHEPHARM.NS
Net Income Common Stockholders,2022-03-31 00:00:00,3853600000.0,JBCHEPHARM.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,JBCHEPHARM.NS
Net Income,2022-03-31 00:00:00,3853600000.0,JBCHEPHARM.NS
Minority Interests,2022-03-31 00:00:00,-6800000.0,JBCHEPHARM.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,3860400000.0,JBCHEPHARM.NS
Net Income Continuous Operations,2022-03-31 00:00:00,3860400000.0,JBCHEPHARM.NS
Tax Provision,2022-03-31 00:00:00,1188600000.0,JBCHEPHARM.NS
Pretax Income,2022-03-31 00:00:00,5049000000.0,JBCHEPHARM.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,392300000.0,JBCHEPHARM.NS
Special Income Charges,2022-03-31 00:00:00,24049000.0,JBCHEPHARM.NS
Other Special Charges,2022-03-31 00:00:00,-24049000.0,JBCHEPHARM.NS
Write Off,2022-03-31 00:00:00,,JBCHEPHARM.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-51200000.0,JBCHEPHARM.NS
Total Other Finance Cost,2022-03-31 00:00:00,3352000.0,JBCHEPHARM.NS
Interest Expense Non Operating,2022-03-31 00:00:00,51200000.0,JBCHEPHARM.NS
Interest Income Non Operating,2022-03-31 00:00:00,9343000.0,JBCHEPHARM.NS
Operating Income,2022-03-31 00:00:00,4707900000.0,JBCHEPHARM.NS
Operating Expense,2022-03-31 00:00:00,11105100000.0,JBCHEPHARM.NS
Other Operating Expenses,2022-03-31 00:00:00,5986100000.0,JBCHEPHARM.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,726600000.0,JBCHEPHARM.NS
Depreciation Income Statement,2022-03-31 00:00:00,726600000.0,JBCHEPHARM.NS
Selling General And Administration,2022-03-31 00:00:00,3160995000.0,JBCHEPHARM.NS
Selling And Marketing Expense,2022-03-31 00:00:00,2581088000.0,JBCHEPHARM.NS
General And Administrative Expense,2022-03-31 00:00:00,579907000.0,JBCHEPHARM.NS
Rent And Landing Fees,2022-03-31 00:00:00,13403000.0,JBCHEPHARM.NS
Gross Profit,2022-03-31 00:00:00,15813000000.0,JBCHEPHARM.NS
Cost Of Revenue,2022-03-31 00:00:00,8429400000.0,JBCHEPHARM.NS
Total Revenue,2022-03-31 00:00:00,24242400000.0,JBCHEPHARM.NS
Operating Revenue,2022-03-31 00:00:00,24242400000.0,JBCHEPHARM.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,JBCHEPHARM.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,JBCHEPHARM.NS
Normalized EBITDA,2021-03-31 00:00:00,,JBCHEPHARM.NS
Total Unusual Items,2021-03-31 00:00:00,1029102000.0,JBCHEPHARM.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,1029102000.0,JBCHEPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,JBCHEPHARM.NS
Reconciled Depreciation,2021-03-31 00:00:00,,JBCHEPHARM.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,JBCHEPHARM.NS
EBITDA,2021-03-31 00:00:00,,JBCHEPHARM.NS
EBIT,2021-03-31 00:00:00,,JBCHEPHARM.NS
Net Interest Income,2021-03-31 00:00:00,,JBCHEPHARM.NS
Interest Expense,2021-03-31 00:00:00,,JBCHEPHARM.NS
Interest Income,2021-03-31 00:00:00,17740000.0,JBCHEPHARM.NS
Normalized Income,2021-03-31 00:00:00,,JBCHEPHARM.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,JBCHEPHARM.NS
Total Expenses,2021-03-31 00:00:00,,JBCHEPHARM.NS
Rent Expense Supplemental,2021-03-31 00:00:00,11486000.0,JBCHEPHARM.NS
Diluted Average Shares,2021-03-31 00:00:00,154564194.0,JBCHEPHARM.NS
Basic Average Shares,2021-03-31 00:00:00,154564194.0,JBCHEPHARM.NS
Diluted EPS,2021-03-31 00:00:00,28.98,JBCHEPHARM.NS
Basic EPS,2021-03-31 00:00:00,28.98,JBCHEPHARM.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,JBCHEPHARM.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,JBCHEPHARM.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,JBCHEPHARM.NS
Net Income,2021-03-31 00:00:00,,JBCHEPHARM.NS
Minority Interests,2021-03-31 00:00:00,,JBCHEPHARM.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,JBCHEPHARM.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,JBCHEPHARM.NS
Tax Provision,2021-03-31 00:00:00,,JBCHEPHARM.NS
Pretax Income,2021-03-31 00:00:00,,JBCHEPHARM.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,JBCHEPHARM.NS
Special Income Charges,2021-03-31 00:00:00,523599000.0,JBCHEPHARM.NS
Other Special Charges,2021-03-31 00:00:00,-524367000.0,JBCHEPHARM.NS
Write Off,2021-03-31 00:00:00,768000.0,JBCHEPHARM.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,JBCHEPHARM.NS
Total Other Finance Cost,2021-03-31 00:00:00,2983000.0,JBCHEPHARM.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,JBCHEPHARM.NS
Interest Income Non Operating,2021-03-31 00:00:00,17740000.0,JBCHEPHARM.NS
Operating Income,2021-03-31 00:00:00,,JBCHEPHARM.NS
Operating Expense,2021-03-31 00:00:00,,JBCHEPHARM.NS
Other Operating Expenses,2021-03-31 00:00:00,,JBCHEPHARM.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,JBCHEPHARM.NS
Depreciation Income Statement,2021-03-31 00:00:00,,JBCHEPHARM.NS
Selling General And Administration,2021-03-31 00:00:00,1980462000.0,JBCHEPHARM.NS
Selling And Marketing Expense,2021-03-31 00:00:00,1770870000.0,JBCHEPHARM.NS
General And Administrative Expense,2021-03-31 00:00:00,209592000.0,JBCHEPHARM.NS
Rent And Landing Fees,2021-03-31 00:00:00,11486000.0,JBCHEPHARM.NS
Gross Profit,2021-03-31 00:00:00,,JBCHEPHARM.NS
Cost Of Revenue,2021-03-31 00:00:00,,JBCHEPHARM.NS
Total Revenue,2021-03-31 00:00:00,,JBCHEPHARM.NS
Operating Revenue,2021-03-31 00:00:00,,JBCHEPHARM.NS
